A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico

@article{DiCesare2002ADB,
  title={A double blind, randomized, placebo-controlled study of SP-303 (Provir) in the symptomatic treatment of acute diarrhea among travelers to Jamaica and Mexico},
  author={Daniel DiCesare and Herbert Dupont and John J. Mathewson and David Ashley and Francisco G Martinez-Sandoval and James E. Pennington and Steven B. Porter},
  journal={American Journal of Gastroenterology},
  year={2002},
  volume={97},
  pages={2585-2588}
}
OBJECTIVE:The study was designed to evaluate the effectiveness of SP-303 (Provir), a plant-derived product with novel antisecretory properties, in the treatment of travelers’ diarrhea.METHODS:A total of 184 persons from the United States who acquired diarrhea in Jamaica or Mexico were enrolled in a double-blind, placebo-controlled study examining the effectiveness of three doses of SP-303 in reducing illness. Subjects were treated with 125 mg, 250 mg, or 500 mg SP-303 or a matching placebo four… 

Tables from this paper

Efficacy and Safety of Crofelemer for Noninfectious Diarrhea in HIV-Seropositive Individuals (ADVENT Trial): A Randomized, Double-Blind, Placebo-Controlled, Two-Stage Study
TLDR
In HIV-seropositive patients taking stable antiretroviral therapy, crofelemer provided significant improvement in diarrhea with a favorable safety profile and was minimally absorbed, well tolerated, did not negatively impact clinical immune parameters, and had a safety profile comparable to placebo.
Crofelemer, a Novel Agent for Treatment of Secretory Diarrhea
TLDR
Oral crofelemer possesses a novel mechanism of action that shows promise in treating secretory diarrhea of several etiologies, however, results from further Phase 3 clinical trials are still needed in order to fully evaluate the efficacy and safety of this agent.
Evaluation of Crofelemer in the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome Patients
TLDR
Crofelelmer did not produce benefit on bowel function; an increase in the number of pain- and discomfort-free days in female D-IBS patients was seen; further studies with crofelemer are warranted to evaluate it as a potential visceral analgesic.
Expert review of the evidence base for self-therapy of travelers' diarrhea.
TLDR
The majority of authors of this document recommended that for all people traveling from low‐risk to high‐risk regions, one of the three antibacterial drugs should be transported with them for self‐treatment of diarrhea that occurs, given in respective order of development for TD therapy: a fluoroquinolone (ciprofloxacin or levofloxac in), rifaximin, or azithromycin.
Nonantimicrobial agents in the prevention and treatment of traveler's diarrhea.
  • C. Ericsson
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2005
TLDR
The antisecretory and antimotility agent loperamide reduces the passage of loose stools by approximately 50% and has been especially useful, in combination with antimicrobial agents, in reducing the total duration of posttreatment diarrhea to a matter of hours.
Randomized Clinical Trial: Crofelemer Treatment in Women With Diarrhea-Predominant Irritable Bowel Syndrome
TLDR
Crofelemer did not significantly improve abdominal pain over placebo by the primary endpoint, however, it did based on the FDA abdominal pain monthly responder endpoint, which suggests that croFelemer may have a role in the treatment of abdominal pain associated with IBS-D.
Acute Traveler’s Diarrhea: Initial Treatment
TLDR
Adult non-pregnant travelers are generally advised to follow smart eating and drinking practices and to bring a supply of bismuth subsalicylate and loperamide, which should be considered as adjunctive therapy in most cases of TD and can similarly be prescribed pre-travel.
Current and future developments in travelers’ diarrhea therapy
TLDR
Rifaximin with an excellent safety profile and limited potential to induce coliform resistance, prevents most of the diarrhea that would otherwise occur and should be given to the routine use of chemoprophylaxis for travelers to high-risk countries.
Therapy for and prevention of traveler's diarrhea.
  • H. Dupont
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2007
TLDR
All persons planning trips to high-risk areas should take with them medication with expected activity against the prevalent bacterial enteropathogens: rifaximin, a fluoroquinolone, or azithromycin for the treatment of common afebrile, nondysenteric diarrhea.
...
...

References

SHOWING 1-10 OF 14 REFERENCES
Treatment of travellers' diarrhoea: zaldaride compared with loperamide and placebo.
TLDR
A zaldaride regimen including a loading dose was shown to be well tolerated and as effective as loperamide in the treatment of travellers' diarrhoea.
Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay).
TLDR
The frequency of resistance among bacterial enteropathogens to traditional antimicrobial agents was particularly high throughout the study period in all 3 regions.
Comparison of loperamide with bismuth subsalicylate for the treatment of acute travelers' diarrhea.
TLDR
It is concluded that loperamide is a safe and effective alternative to bismuth subsalicylate for the treatment of nondysenteric travelers' diarrhea.
Adverse effect of lomotil therapy in shigellosis.
TLDR
Diarrhea may represent a defense mechanism when disease is caused by a bacterial pathogen that must penetrate the intestinal epithelium to produce illness where increased intestinal motility (diarrhea) may decrease contact time between the invasive bacteria and mucosal cells.
Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea.
Racecadotril in the treatment of acute watery diarrhea in children.
TLDR
In young boys with acute watery diarrhea, racecadotril is an effective and safe treatment and the intake of oral rehydration solution was significantly lower in the racec Cadotril group than in the placebo group (P<0.001).
A novel plant-derived inhibitor of cAMP-mediated fluid and chloride secretion.
TLDR
SP-303 may prove to be a useful broad-spectrum antidiarrheal agent that shows efficacy against in vivo cholera toxin-induced fluid secretion and in vitro cAMP-mediated Cl- secretion.
Intestinal electrolyte transport and diarrheal disease.
...
...